


Healthcare Industry News: HIV/AIDS
News Release - February 7, 2011
FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women
Source: Bristol-Myers Squibb
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
